SCHEMBL4928860

SCHEMBL4928860

CC1(C)CC(=O)c2c(S(C)(=O)=O)sc(C(=O)OCCc3ccccc3C(F)(F)F)c2C1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.47
PKM P14618 2/20 0.47
LRRK2 Q5S007 1/20 0.39
ALOX5 P09917 1/20 0.37
KDM4E B2RXH2 3/20 0.35
LMNA P02545 2/20 0.35
MAPT P10636 1/20 0.35
EGFR P00533 1/20 0.35
ERBB2 P04626 1/20 0.35
PDGFRB P09619 1/20 0.35
KDR P35968 1/20 0.35
NPSR1 Q6W5P4 2/20 0.35
OPRM1 P35372 1/20 0.33
CACNA1G O43497 1/20 0.33
CACNA1H O95180 1/20 0.33
CACNA1I Q9P0X4 1/20 0.33
PPARG P37231 2/20 0.33
PPARA Q07869 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4929847 0.91 ALDH1A1 (0.48) ALDH1A1PKMLRRK2KDM4ELMNA
SCHEMBL4918258 0.81 ALDH1A1 (0.47) ALDH1A1PKMLRRK2KDM4ELMNA
SCHEMBL4922139 0.80 ALDH1A1 (0.52) ALDH1A1PKMLRRK2KDM4ELMNA
SCHEMBL13791613 0.78 ALDH1A1 (0.54) ALDH1A1PKMLRRK2KDM4ELMNA
SCHEMBL4930275 0.78 ALDH1A1 (0.50) ALDH1A1PKMLRRK2KDM4ELMNA
SCHEMBL4929581 0.77 ALDH1A1 (0.46) ALDH1A1PKMLRRK2KDM4ELMNA
SCHEMBL4922937 0.76 ALDH1A1 (0.46) ALDH1A1PKMKDM4ELMNAMAPT
SCHEMBL4927984 0.75 ALDH1A1 (0.50) ALDH1A1PKMLRRK2KDM4ELMNA
SCHEMBL4929155 0.72 ALDH1A1 (0.52) ALDH1A1PKMLRRK2KDM4ELMNA
SCHEMBL4937751 0.72 ALDH1A1 (0.49) ALDH1A1PKMLRRK2KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275066-A1 Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists NOVO NORDISK A/S (DK) 2008-11-06 US disclosed
US-20080275066-A1 Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists NOVO NORDISK A/S (DK) 2008-11-06 US disclosed
US-20080275066-A1 Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists NOVO NORDISK A/S (DK) 2008-11-06 US disclosed
EP-1765814-A1 CONDENSED THIOPHENE DERIVATIVES AND THEIR USE AS CYCLIC GLP-1 AGONISTS NOVO NORDISK A/S (DK) 2007-03-28 EP disclosed
WO-2006003096-A1 CONDENSED THIOPHENE DERIVATIVES AND THEIR USE AS CYCLIC GLP-1 AGONISTS NOVO NORDISK A/S (DK) 2006-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275066-A1 Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists GLP1R, GIPR, GCGR ALDH1A1 2002/4885PKM 2177/4885LRRK2 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.